【瞩目】东阳光药入局大涨82%潜力注射剂

米内网
Feb 11

精彩内容日前,CDE官网显示,乳源东阳光药业的注射用硫酸艾沙康唑以仿制4类报产获受理。米内网数据显示,注射用硫酸艾沙康唑在2024年中国三大终端六大市场销售额近2亿元,2025年Q1-Q3同比增长82.17%,是全身用抗真菌化药注射剂TOP5产品。来源:米内网一键检索注射用硫酸艾沙康唑是一种广谱三唑类抗真菌药物,主要用于治疗侵袭性曲霉病和毛霉病等严重真菌感染。近年中国三大终端六大市场注射用硫酸...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10